Prostate cancer gets first gene-targeted medicines 21 May 2020 The Institute of Cancer Research, London, has strongly welcomed the approval by the US Food and Drug Administration (FDA) of the genetically targeted drug olaparib for some men with advanced prostate cancer. Find out more Show/Hide
Approval of targeted therapies first line for prostate cancer ‘will ease COVID-19 pressures’ 06 May 2020 The Institute of Cancer Research, London, has broadly welcomed the approval of targeted hormone therapies enzalutamide and abiraterone as first-line NHS treatments for men with advanced prostate cancer. Find out more Show/Hide
Most innovative cancer drugs facing delays in reaching patients 29 Jan 2020 Despite increasing numbers of cancer drugs being licensed, an analysis has found that highly innovative drugs took longer to reach NHS patients than more conventional treatments. Find out more Show/Hide
The ICR responds to decision by NICE not to recommend pembrolizumab as first-line treatment for advanced head and neck cancer 15 Jan 2020
The ICR responds to approval of abiraterone as first-line treatment for advanced prostate cancer on the NHS in Scotland 13 Jan 2020
ICR responds to NICE approval of palbociclib for treating advanced breast cancer after hormone therapy 28 Nov 2019
Experts call for genetic testing to personalise treatment for all children assessed for new cancer treatments 26 Sep 2018